Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2005 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (314)	1/5/2006 9:49:20 PM
From: former_pgs	Read Replies (1) \| Respond to of 322

From the limited reading i do in this area, the aspect that fascinates me the most (and likely confounds drug development) is the fact that activation of certain toll-like receptors induces a local response whereas others may not induce a strong local response but a more effective systemic one. So a class of drugs targeting this mechanism will probably require an extra level of research into modes of administration above and beyond the usual IV-versus-pill debate. As a rule, I don't like ODN drugs. But me not liking something shouldn't surprise anyone :-)